Skip to content
10-Q

Quarterly Report

Indaptus Therapeutics, Inc. INDP

0001493152-26-023362

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 15, 2026 113.24M sh
Shares Diluted Q1 2026 · Mar 31, 2026 10.96M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 497.79K sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$7.01M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$5.05M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $1.5M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $8.51M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.25M
Stockholders Equity Q1 2026 · Dec 31, 2025 $3.15M
Stockholders Equity Q1 2026 · Mar 31, 2025 $2.8M
Stockholders Equity Q1 2026 · Dec 31, 2024 $3.94M
Current Liabilities Q1 2026 · Mar 31, 2026 $933K
Current Liabilities Q1 2026 · Dec 31, 2025 $6.16M
Current Assets Q1 2026 · Mar 31, 2026 $2.18M
Current Assets Q1 2026 · Dec 31, 2025 $9.31M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.23
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$9.11
Eps Basic Q1 2026 · Mar 31, 2026 −$0.23
Eps Basic restated Q1 2026 · Mar 31, 2025 −$9.11
Sga Expense Q1 2026 · Mar 31, 2026 $1.67M
Sga Expense Q1 2026 · Mar 31, 2025 $1.76M
Rd Expense Q1 2026 · Mar 31, 2026 $491.13K
Rd Expense Q1 2026 · Mar 31, 2025 $2.81M
Net Income Q1 2026 · Mar 31, 2026 −$2.54M
Net Income Q1 2026 · Mar 31, 2025 −$4.53M
Operating Income Q1 2026 · Mar 31, 2026 −$2.16M
Operating Income Q1 2026 · Mar 31, 2025 −$4.57M